CCR5/CCL5 Links Mitochondrial Dysfunction to Angiotensin II Vascular Injury

This study demonstrates that Angiotensin II exacerbates vascular injury by amplifying CCL5/CCR5 signaling, which drives mitochondrial dysfunction and oxidative stress in vascular smooth muscle cells, thereby promoting vascular inflammation and impairment.

The Gist

The Big Picture: A Traffic Jam in Your Blood Vessels

Imagine your blood vessels are like a busy highway system. For traffic to flow smoothly, the road needs to be clear, and the traffic lights (which control how wide the road opens or closes) need to work perfectly.

In people with high blood pressure (hypertension), this highway gets clogged. The "traffic lights" get stuck, the road walls get thick and stiff, and the whole system breaks down.

This study investigates why this happens. The researchers discovered a specific chain reaction:

1. A stress hormone called Angiotensin II (let's call it the "Stress Signal") turns up the volume on a chemical messenger called CCL5.
2. This messenger activates a receptor on the vessel walls called CCR5 (think of it as a "doorbell").
3. When this doorbell rings too much, it breaks the power plants inside the vessel cells.
4. Broken power plants cause the traffic lights to malfunction, leading to high blood pressure and damaged roads.

---

The Cast of Characters

• Angiotensin II (The Stress Signal): The boss that tells the body to tighten up blood vessels. In this story, it's the one starting the trouble.
• CCL5 (The Messenger): A chemical that usually helps call in the immune system (like calling an ambulance). But in this case, it's being overused.
• CCR5 (The Doorbell): A receptor on the surface of blood vessel cells. When CCL5 rings the doorbell, the cell reacts.
• Mitochondria (The Power Plants): Tiny factories inside every cell that generate energy. They also manage the cell's "battery charge."
• Vascular Smooth Muscle Cells (The Road Workers): The cells that make up the walls of your blood vessels. They decide whether to squeeze the vessel tight or relax it.

---

The Story: How the Highway Gets Clogged

1. The Stress Signal Turns Up the Volume

The researchers found that when the body is under stress (due to Angiotensin II), it produces way too much of the messenger CCL5. It's like a fire alarm that won't stop ringing.

Even worse, the stress signal tells the blood vessel cells to install more doorbells (CCR5). So, not only is the alarm ringing louder, but there are also more doors to ring it. This makes the blood vessels hypersensitive to the stress.

2. The Doorbell Breaks the Power Plants

When the CCL5 messenger rings the CCR5 doorbell too often, it doesn't just wake up the cell; it breaks the cell's power plants (mitochondria).

• The Battery Drains: The power plants lose their ability to generate energy efficiently. They run out of "reserve fuel."
• The Short Circuit: The broken power plants start leaking toxic waste, known as oxidative stress (or free radicals). Imagine a factory that starts spewing smoke and sparks instead of making products.

3. Two Different Types of Damage

The study found that this broken power plant causes two different problems, like two different types of traffic jams:

• Problem A: The Traffic Light Stuck on Red (Endothelial Dysfunction)
  The toxic smoke (oxidative stress) from the broken power plants ruins the "traffic lights" on the inside of the vessel. These lights are supposed to tell the vessel to relax and open up. Because the smoke is there, the lights get stuck, and the vessel can't relax.

  • The Fix: If you give the cells a "smoke scrubber" (an antioxidant), the lights start working again, and the vessel can relax.

• Problem B: The Road Workers Getting Stiff (Hypercontractility)
  The road workers (muscle cells) themselves get stiff and tight. They don't just stay open; they clamp down hard. This happens because the power plants are so broken that the workers can't get the energy they need to relax.

  • The Fix: Surprisingly, the "smoke scrubber" didn't fix this. The stiffness wasn't caused by the smoke; it was caused by the total lack of energy and the broken battery.

4. The "Missing Link" Discovery

The researchers tested this by using mice that were genetically engineered to lack the doorbell (CCR5).

• When these mice were exposed to the Stress Signal (Angiotensin II), they stayed healthy. Their power plants didn't break, and their blood vessels didn't get clogged.
• This proved that the CCR5 doorbell is the essential link. Without it, the stress signal can't break the power plants.

Why Does This Matter? (The "So What?")

This is a big deal for two reasons:

1. New Way to Treat High Blood Pressure: Currently, most blood pressure meds try to stop the "Stress Signal" (Angiotensin II) or force the vessels to open. This study suggests we could also block the doorbell (CCR5). If we stop the doorbell from ringing, we stop the power plants from breaking.
2. Existing Medicine: There is already a drug called Maraviroc that blocks the CCR5 doorbell. It is currently used to treat HIV. This study suggests that this drug might also be repurposed to help people with high blood pressure, especially those whose condition is driven by inflammation.

The Takeaway Analogy

Imagine your blood vessel is a car engine.

• Angiotensin II is the driver pressing the gas pedal too hard.
• CCL5/CCR5 is a faulty sensor that tells the engine to rev even higher.
• Mitochondria are the spark plugs.
• Because the sensor is faulty, the spark plugs get fried (mitochondrial dysfunction).
• The car starts sputtering (endothelial dysfunction) and the brakes lock up (stiff vessels).

This paper says: "Don't just try to take your foot off the gas. If you fix the faulty sensor (block CCR5), the spark plugs won't fry, and the engine will run smoothly again."

Summary in One Sentence

High blood pressure damages blood vessels because a stress signal triggers a chemical messenger that rings a specific receptor, which in turn breaks the cell's power plants, causing the vessels to get stiff and unable to relax; blocking that receptor could be a new way to fix the damage.

Technical Summary

1. Problem Statement

Hypertension is characterized by vascular inflammation, endothelial dysfunction, and structural remodeling, largely driven by Angiotensin II (Ang II). While the role of the chemokine CCL5 (RANTES) and its receptor CCR5 in recruiting immune cells during Ang II-induced hypertension is established, the intracellular mechanisms linking CCL5/CCR5 activation to direct vascular dysfunction remain unclear. Specifically, it is unknown whether Ang II amplifies CCL5/CCR5 signaling within vascular cells and how this signaling translates into mitochondrial dysfunction, oxidative stress, and altered vascular reactivity.

2. Methodology

The study employed a combination of in vivo animal models, ex vivo vascular physiology, and in vitro cellular assays:

• Animal Models:
  • Subjects: Wild-type (CCR5+/+) and global CCR5-deficient (CCR5−/−) male mice.
  • Interventions:
    • Ang II Infusion: 14-day subcutaneous infusion (490 ng/min/kg) to induce hypertension.
    • CCL5 Infusion: 14-day infusion of recombinant CCL5 (0.42 ng/day) to mimic circulating levels seen in Ang II-treated mice.
  • Controls: Vehicle-treated groups.
• Vascular Physiology:
  • Reactivity: Wire myography and pressure myography were used on thoracic aorta and mesenteric arteries to assess contractility (Phenylephrine), endothelium-dependent relaxation (Acetylcholine), and endothelium-independent relaxation (Sodium Nitroprusside).
  • Remodeling: Histological analysis (Masson's trichrome) and morphometric measurements (media-to-lumen ratio, cross-sectional area).
  • Pharmacology: Use of Maraviroc (CCR5 antagonist), MnTMPyP (mitochondrial antioxidant/SOD2 mimetic), and CCCP (mitochondrial uncoupler).
• Cellular & Molecular Assays:
  • Cell Model: Rat Aortic Smooth Muscle Cells (RASMCs).
  • Mitochondrial Function: Seahorse XF analyzer for Oxygen Consumption Rate (OCR); JC-1 dye for membrane potential; MitoSOX for mitochondrial superoxide; Amplex Red for H₂O₂.
  • Gene/Protein Expression: RT-PCR and Western blotting for inflammatory markers, mitochondrial dynamics proteins (OPA1, COX-4), and chemokine receptors.
  • Proteomics: Cytokine array and ELISA to quantify circulating chemokines.

3. Key Contributions

• Mechanistic Link: The study establishes a direct causal link between the inflammatory chemokine axis (CCL5/CCR5) and mitochondrial bioenergetic failure in vascular smooth muscle cells (VSMCs).
• Dual-Pathway Discovery: It differentiates the mechanisms driving two distinct aspects of vascular injury:
  1. Endothelial Dysfunction: Driven primarily by mitochondrial Reactive Oxygen Species (mitoROS).
  2. Vascular Hypercontractility: Driven by sustained disruption of mitochondrial membrane potential and bioenergetic reserve, largely independent of acute ROS.
• Ang II Amplification: Demonstrates that Ang II does not just increase circulating CCL5 but also upregulates CCR5 expression on VSMCs, creating a feed-forward loop that sensitizes the vasculature to inflammatory stimuli.

4. Key Results

A. Ang II Amplifies CCL5/CCR5 Signaling

• Ang II infusion significantly increased circulating CCL5 levels and upregulated CCR5, CCR1, and CCR3 expression in vascular tissues and VSMCs.
• Ang II treatment directly increased CCR5 expression in VSMCs without altering CCL5 expression, suggesting Ang II primes VSMCs to be hyper-responsive to CCL5.

B. CCR5 is Essential for Ang II-Induced Injury

• CCR5 Deficiency: CCR5−/− mice were protected against Ang II-induced vascular hypercontractility, endothelial dysfunction, perivascular adipose tissue (PVAT) dysfunction, and vascular remodeling (hypertrophy).
• Inflammation: Ang II increased inflammatory markers (ICAM-1, VCAM-1, CCL2, IL-6) in wild-type vessels, but this response was abolished in CCR5−/− mice.

C. CCL5 Directly Induces Dysfunction Without Remodeling

• Infusing recombinant CCL5 (at levels matching Ang II treatment) reproduced vascular dysfunction (increased contractility, impaired relaxation) and inflammation.
• Crucial Distinction: Unlike Ang II, CCL5 infusion did not cause structural vascular remodeling (media-to-lumen ratio changes) over 14 days, suggesting CCR5 signaling is necessary but not sufficient for structural hypertrophy without other Ang II-mediated pathways (e.g., mechanical stress).

D. Mitochondrial Dysfunction Mechanisms

• Respiration: CCL5 treatment in VSMCs increased basal respiration but significantly reduced maximal respiratory capacity and reserve capacity, indicating energy exhaustion.
• Membrane Potential: CCL5 caused mitochondrial depolarization (reduced JC-1 red/green ratio) and altered mitochondrial network organization (increased OPA1 expression).
• Oxidative Stress: CCL5 increased mitochondrial superoxide (MitoSOX) and H₂O₂ production in a CCR5-dependent manner.

E. Differential Impact on Vascular Reactivity

• Endothelial Function: Treatment with the mitochondrial antioxidant MnTMPyP restored endothelium-dependent relaxation in CCL5-treated vessels, confirming that mitoROS mediates endothelial dysfunction.
• Contractility: MnTMPyP failed to normalize the enhanced contractility (hypercontractility) induced by CCL5. Furthermore, the mitochondrial uncoupler CCCP did not worsen dysfunction in CCL5-treated vessels, suggesting the bioenergetic system was already chronically impaired.
• Conclusion: Hypercontractility is driven by sustained bioenergetic failure and membrane potential loss, not acute ROS excess.

5. Significance and Clinical Implications

• Therapeutic Target: The study identifies the CCL5/CCR5-mitochondrial axis as a novel therapeutic target for hypertension.
• Repurposing Drugs: Since CCR5 antagonists (e.g., Maraviroc) are already FDA-approved for HIV, they could be repurposed to treat inflammatory phenotypes of hypertension by preserving mitochondrial function and reducing vascular injury.
• Precision Medicine: The findings suggest that targeting chemokine signaling could provide vascular protection beyond simple blood pressure reduction, particularly in patients with immune-activated or inflammatory hypertension.
• Limitations & Future: While CCL5 caused functional impairment, it did not induce structural remodeling in this timeframe. Future studies need to explore longer-term exposure and the potential for combination therapies targeting both inflammation and mitochondrial bioenergetics.

In summary, this paper redefines the pathophysiology of Ang II-induced vascular injury by positioning mitochondrial dysfunction as the central effector of CCR5 signaling, offering a new mechanistic explanation for vascular inflammation and a potential pathway for novel therapeutic interventions.